{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:46:31Z","timestamp":1790826391291,"version":"4.1.0"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T00:00:00Z","timestamp":1393372800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0089612","type":"journal-article","created":{"date-parts":[[2014,2,26]],"date-time":"2014-02-26T22:06:22Z","timestamp":1393452382000},"page":"e89612","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":121,"title":["Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI: Randomized, Placebo-Controlled Phase II Clinical Trial in Patients with Latent Tuberculosis Infection"],"prefix":"10.1371","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct01136161","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andre S.","family":"Nell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"D\u2019lom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bouic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Sabat\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Bosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Picas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Amat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Churchyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere-Joan","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,2,26]]},"reference":[{"key":"ref1","unstructured":"World Health Organization. Global tuberculosis control: epidemiology s, financing: WHO report 2011."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0966-842X(98)01216-5","article-title":"Mechanisms of latency in Mycobacterium tuberculosis","volume":"6","author":"NM Parrish","year":"1998","journal-title":"Trends Microbiol"},{"key":"ref3","unstructured":"Harris A MD, Graham. (2004) TB\/HIV a clinical manual. 2nd Edition. WHO."},{"key":"ref4","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"GW Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00005-009-0062-5","article-title":"Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease","volume":"58","author":"PJ Cardona","year":"2010","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tube.2006.01.024","article-title":"RUTI: a new chance to shorten the treatment of latent tuberculosis infection","volume":"86","author":"PJ Cardona","year":"2006","journal-title":"Tuberculosis (Edinb)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s15010-008-8087-y","article-title":"A dynamic reinfection hypothesis of latent tuberculosis infection","volume":"37","author":"PJ Cardona","year":"2009","journal-title":"Infection"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.vaccine.2009.09.134","article-title":"Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI","volume":"28","author":"C Vilaplana","year":"2010","journal-title":"Vaccine"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1086\/592450","article-title":"A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers","volume":"198","author":"DF Hoft","year":"2008","journal-title":"J Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers","volume":"28","author":"JT van Dissel","year":"2010","journal-title":"Vaccine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.vaccine.2010.12.135","article-title":"Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection","volume":"29","author":"JT van Dissel","year":"2011","journal-title":"Vaccine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.beem.2010.12.001","article-title":"Adipose tissue biology and HIV-infection","volume":"25","author":"M Giralt","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.4161\/hv.8570","article-title":"The candidate tuberculosis vaccine Mtb72F\/AS02A: Tolerability and immunogenicity in humans","volume":"5","author":"K Von Eschen","year":"2009","journal-title":"Hum Vaccin"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1089\/aid.2009.0015","article-title":"Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients","volume":"25","author":"P Castro","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/S0264-410X(00)00519-3","article-title":"Tuberculosis subunit vaccine development: on the role of interferon-gamma","volume":"19","author":"EM Agger","year":"2001","journal-title":"Vaccine"},{"key":"ref16","first-page":"1068","article-title":"Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis","volume":"10","author":"SH Kaufmann","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tube.2003.08.010","article-title":"Immunology of tuberculosis and implications in vaccine development","volume":"84","author":"JL Flynn","year":"2004","journal-title":"Tuberculosis (Edinb)"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1371\/journal.pmed.0050145","article-title":"Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations","volume":"5","author":"WA Hanekom","year":"2008","journal-title":"PLoS Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1172\/JCI46252","article-title":"Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection","volume":"122","journal-title":"J Clin Invest"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1128\/CVI.00094-08","article-title":"Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis","volume":"15","author":"E Guirado","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1086\/590185","article-title":"Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa","volume":"198","author":"T Hawkridge","year":"2008","journal-title":"J Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1164\/rccm.200809-1486OC","article-title":"Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals","volume":"179","author":"CR Sander","year":"2009","journal-title":"Am J Respir Crit Care Med"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0089612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T22:26:29Z","timestamp":1540247189000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0089612"}},"subtitle":[],"editor":[{"given":"Ray","family":"Borrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,26]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,2,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0089612","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,26]]}}}